Balyasny Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Balyasny Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$657K	Buy	+27,066	New	+$461K	﹤0.01%	2405
2026 Q1	–	Sell	-118,481	Closed	-$2.25M	–	3318
2025 Q4	$2.25M	Sell	118,481 -3,102	-3%	-$44.6K	﹤0.01%	1799
2025 Q3	$1.12M	Buy	+121,583	New	+$1.26M	﹤0.01%	2067
2024 Q1	–	Sell	-22,581	Closed	-$233K	–	2953
2023 Q4	$233K	Sell	22,581 -3,694	-14%	-$25.3K	﹤0.01%	2265
2023 Q3	$207K	Buy	+26,275	New	+$240K	﹤0.01%	2026
2022 Q4	–	Sell	-15,930	Closed	-$208K	–	3078
2022 Q3	$208K	Buy	+15,930	New	+$252K	﹤0.01%	2301
2021 Q3	–	Sell	-78,527	Closed	-$2.08M	–	2274
2021 Q2	$2.08M	Buy	78,527 +35,072	+81%	+$1.03M	0.01%	994
2021 Q1	$1.35M	Buy	+43,455	New	+$1.64M	0.01%	1162

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management's NRIX Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 27,066 shares worth $657K. The stake represents ﹤0.01% of the portfolio and ranks #2405 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in NRIX as recently as Q4 2025.

Balyasny Asset Management first reported a position in NRIX in Q1 2021 and has held it in 8 quarters since. The position peaked at $2.25M in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Balyasny Asset Management held 27,066 shares of Nurix Therapeutics worth $657K as of Q2 2026.
Nurix Therapeutics was a new Balyasny Asset Management position in Q2 2026.
Nurix Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2405 holding.
Balyasny Asset Management first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 8 quarters since.
Balyasny Asset Management's Nurix Therapeutics position peaked at $2.25M in Q4 2025.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.